These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 15963813

  • 1. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
    Smith JA, Ngo H, Martin MC, Wolf JK.
    Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
    [Abstract] [Full Text] [Related]

  • 2. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, Scottish Gynaecological Cancer Trials Group.
    J Natl Cancer Inst; 2004 Nov 17; 96(22):1682-91. PubMed ID: 15547181
    [Abstract] [Full Text] [Related]

  • 3. Current status of taxane and platinum-based chemotherapy in ovarian cancer.
    McGuire WP.
    J Clin Oncol; 2003 May 15; 21(10 Suppl):133s-135s. PubMed ID: 12743128
    [Abstract] [Full Text] [Related]

  • 4. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 May 15; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 5. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.
    Gynecol Oncol; 2004 Jul 15; 94(1):67-73. PubMed ID: 15262121
    [Abstract] [Full Text] [Related]

  • 6. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.
    Minagawa Y, Kigawa J, Kanamori Y, Itamochi H, Terakawa N, Okada M, Kitada F.
    Gynecol Oncol; 2006 Jun 15; 101(3):495-8. PubMed ID: 16375950
    [Abstract] [Full Text] [Related]

  • 7. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb 15; 14(75):16-8. PubMed ID: 15751170
    [Abstract] [Full Text] [Related]

  • 8. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
    Vasey PA.
    J Clin Oncol; 2003 May 15; 21(10 Suppl):136s-144s. PubMed ID: 12743129
    [Abstract] [Full Text] [Related]

  • 9. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
    Nomura H, Aoki D, Michimae H, Mizuno M, Nakai H, Arai M, Sasagawa M, Ushijima K, Sugiyama T, Saito M, Tokunaga H, Matoda M, Nakanishi T, Watanabe Y, Takahashi F, Saito T, Yaegashi N, Japanese Gynecologic Oncology Group.
    JAMA Oncol; 2019 Jun 01; 5(6):833-840. PubMed ID: 30896757
    [Abstract] [Full Text] [Related]

  • 10. Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
    Engblom P, Rantanen V, Kulmala J, Grènman S.
    Cancer; 1999 Nov 15; 86(10):2066-73. PubMed ID: 10570433
    [Abstract] [Full Text] [Related]

  • 11. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
    Ozols RF.
    Semin Oncol; 1995 Dec 15; 22(6 Suppl 15):1-6. PubMed ID: 8643963
    [Abstract] [Full Text] [Related]

  • 12. In vitro responses of ovarian cancers to platinums and taxanes.
    Kornblith P, Wells A, Gabrin MJ, Piwowar J, Chattopadhyay A, George LD, Ochs RL, Burholt D.
    Anticancer Res; 2003 Dec 15; 23(1B):543-8. PubMed ID: 12680143
    [Abstract] [Full Text] [Related]

  • 13. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC.
    Gynecol Oncol; 2009 Dec 15; 115(3):377-81. PubMed ID: 19800107
    [Abstract] [Full Text] [Related]

  • 14. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karphathios S, Papakostas P, Bamia C, Fountzilas G.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [Abstract] [Full Text] [Related]

  • 15. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR.
    Cancer Res; 1993 Jun 01; 53(11):2581-6. PubMed ID: 8388318
    [Abstract] [Full Text] [Related]

  • 16. Carboplatin versus cisplatin in ovarian cancer.
    Alberts DS.
    Semin Oncol; 1995 Oct 01; 22(5 Suppl 12):88-90. PubMed ID: 7481869
    [Abstract] [Full Text] [Related]

  • 17. Platinum compounds in the treatment of advanced breast cancer.
    Martín M.
    Clin Breast Cancer; 2001 Oct 01; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [Abstract] [Full Text] [Related]

  • 18. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
    Stamelos VA, Robinson E, Redman CW, Richardson A.
    Gynecol Oncol; 2013 Feb 01; 128(2):377-82. PubMed ID: 23168176
    [Abstract] [Full Text] [Related]

  • 19. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
    Potamianou A, Androulakis N, Papakotoulas P, Toufexi H, Latoufis C, Kouroussis C, Christofilakis C, Xenidis N, Georgoulias V, Polyzos A.
    Oncology; 2005 Feb 01; 69(4):348-53. PubMed ID: 16293974
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E, Guastalla JP, Weber B, Curé H, Orfeuvre H, Mousseau M, Vincent P, Diéras V, Tubiana-Mathieu N, Jacquin JP, Mignot L, Leduc B, Paraïso D, Viens P.
    Semin Oncol; 1997 Oct 01; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.